EBV T-cell immunotherapy generated by peptide selection has enhanced effector functionality compared to LCL stimulation

• Published in: Frontiers in immunology Vol. 15; p. 1412211
• Main Authors: Cooper, Rachel S, Sutherland, Catherine, Smith, Linda M, Cowan, Graeme, Barnett, Mark, Mitchell, Donna, McLean, Colin, Imlach, Stuart, Hayes, Alan, Zahra, Sharon, Manchanayake, Champa, Vickers, Mark A, Graham, Gerry, McGowan, Neil W A, Turner, Marc L, Campbell, John D M, Fraser, Alasdair R
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 01-07-2024
• Subjects: Cell Line, Transformed; cell therapy; Epstein-Barr virus; Epstein-Barr Virus Infections - immunology; Epstein-Barr Virus Infections - therapy; Herpesvirus 4, Human - immunology; Humans; Immunology; immunotherapy; Immunotherapy, Adoptive - methods; Lymphocyte Activation - immunology; peptide; Peptides - immunology; potency; T cell; T-Lymphocytes - immunology; peptide; potency; T cell receptor; T cell; cell therapy; immunotherapy; lymphoblastoid cell line; Epstein-Barr virus
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2024.1412211

Adoptive immunotherapy with Epstein-Barr virus (EBV)-specific T cells is an effective treatment for relapsed or refractory EBV-induced post-transplant lymphoproliferative disorders (PTLD) with overall survival rates of up to 69%. EBV-specific T cells have been conventionally made by repeated stimulation with EBV-transformed lymphoblastoid cell lines (LCL), which act as antigen-presenting cells. However, this process is expensive, takes many months, and has practical risks associated with live virus. We have developed a peptide-based, virus-free, serum-free closed system to manufacture a bank of virus-specific T cells (VST) for clinical use. We compared these with standard LCL-derived VST using comprehensive characterization and potency assays to determine differences that might influence clinical benefits. Multi-parameter flow cytometry revealed that peptide-derived VST had an expanded central memory population and less exhaustion marker expression than LCL-derived VST. A quantitative HLA-matched allogeneic cytotoxicity assay demonstrated similar specific killing of EBV-infected targets, though peptide-derived EBV T cells had a significantly higher expression of antiviral cytokines and degranulation markers after antigen recall. High-throughput T cell receptor-beta (TCRβ) sequencing demonstrated oligoclonal repertoires, with more matches to known EBV-binding complementary determining region 3 (CDR3) sequences in peptide-derived EBV T cells. Peptide-derived products showed broader and enhanced specificities to EBV nuclear antigens (EBNAs) in both CD8 and CD4 compartments, which may improve the targeting of highly expressed latency antigens in PTLD. Importantly, peptide-based isolation and expansion allows rapid manufacture and significantly increased product yield over conventional LCL-based approaches.